Dergiler / The Anatolian Journal of Cardiology / 2016 / Cilt: 16 - Sayı: 5

Galectin-3 levels in patients with hypertrophic cardiomyopathy and its relationship with left ventricular mass index and function

Sayfa
344–348
DOI
—
🏛️Bu makalenin bibliyografik verileri ve tam metin bağlantısı DergiPark üzerinden sağlanmıştır.
DergiPark Kaydı ↗
✨

Yapay Zeka Hızlı Bakış & Çıkarımlar

AI Insight
⚡ TL;DR(1 Cümlede Hızlı Çıkarım)

Gal-3 is not a good marker of decreased myocardial LV diastolic and systolic functions in these patients.

📌 3 Maddede Bu Makale

🎯
Amaç & Hipotez:Objective: Cardiac fibrosis is an important contributor to adverse left ventricular (LV) remodeling and arrhythmias in patients with hypertrophic cardiomyopathy (HCM).
📊
Temel Bulgular & Veri:Galectin-3 (Gal-3) is a novel marker of cardiac fibrosis and inflammation.
💡
Sonuç & Katkı:Gal-3 is not a good marker of decreased myocardial LV diastolic and systolic functions in these patients.
🔬Tür:Modelleme & Sayısal Simülasyon
📍Kapsam:Genişletilmiş Akademik Örneklem
⚙️Değişkenler:Alan Parametreleri

Abstract

Objective: Cardiac fibrosis is an important contributor to adverse left ventricular (LV) remodeling and arrhythmias in patients with hypertrophic cardiomyopathy (HCM). Galectin-3 (Gal-3) is a novel marker of cardiac fibrosis and inflammation. In this study, we investigated Gal-3 levels in patients with HCM and controls and assessed the relationship between Gal-3 level and echocardiographic indices using strain echocardiography in patients with HCM.Methods: Forty patients with HCM in sinus rhythm and 35 healthy controls were prospectively enrolled in this case-control study. The HCM diagnosis was based on two-dimensional echocardiographic demonstration of a hypertrophied and non-dilated left ventricle (LV) with a wall thickness >=15 mm in one or more LV myocardial segments in the absence of any cardiac or systemic disease capable of inducing LV hypertrophy. Patients with one of the followings were excluded: coronary artery disease, atrial fibrillation episodes on 24-h Holter electrocardiogram (ECG) monitoring, history of an invasive intervention to alleviate an LV outflow (LVOT) obstruction, inadequate image quality, renal disease, diabetes mellitus, hyperlipidemia, liver cirrhosis, and pulmonary fibrosis. Global LV longitudinal, circumferential strain and strain rates, peak torsion, and LV mass index (LVMI) of all subjects were assessed by echocardiography. Gal-3 levels were measured in all subjects.Results: Left ventricular global longitudinal strain (-13.37±4.6% vs. -18.93±2.5%, p<0.001) and strain rate (0.66±0.22 s-1 vs. 1.08±0.14 s-1, respectively; p<0.001) values were lower in patients with HCM than in controls. Gal-3 levels were significantly higher in patients with HCM than in controls (16.9±6.64 ng/mL vs. 13.21±3.42 ng/mL, p=0.005). Gal-3 levels were associated with the thickness of the interventricular septum (r=0.444, p=0.004) and LVMI (r=0.365, p=0.021); however, they were not associated with LV global longitudinal strain (p=0.42) or strain rate (p=0.28).Conclusion: Gal-3 levels increased and were correlated with the degree of LV hypertrophy in patients with HCM. Gal-3 is not a good marker of decreased myocardial LV diastolic and systolic functions in these patients.

🔖

Bu Makaleye Atıf Yap

YAKAR, S. T., TÜLÜCE, K., ÇİL, Z., EMREN, S. V., AKYILDIZ, Z. İ., ERGENE, O. (2016). Galectin-3 levels in patients with hypertrophic cardiomyopathy and its relationship with left ventricular mass index and function. The Anatolian Journal of Cardiology, Cilt: 16 - Sayı: 5, 344–348. https://ajindex.com/articles/365508

📄 Tam Metin PDF Okuyucu

📄

PDF görüntüleyici hazırlanıyor...

Kaynakça (10)

  1. Basso C, Thiene G, Corrado D, Buja G, Melacini P, Nava A. Hypertrophic cardiomyopathy and sudden death in the young: pathologic evidence of myocardial ischemia. Hum Pathol 2000; 31: 988-98
  2. Olivotto I, Maron BJ, Appelbaum E, Harrigan CJ, Salton C, Gibson CM, et al. Spectrum and clinical significance of systolic function and myocardial fibrosis assessed by cardiovascular magnetic resonance in hypertrophic cardiomyopathy. Am J Cardiol 2010; 106: 261-7
  3. Kobayashi T, Popovic Z, Bhonsale A, Smedira NG, Tan C, Rodriguez ER, et al. Association between septal strain rate and histopathology in symptomatic hypertrophic cardiomyopathy patients undergoing septal myectomy. Am Heart J 2013; 166: 503-11
  4. Popovic ZB, Kwon DH, Mishra M, Buakhamsri A, Greenberg NL, Thamilarasan M, et al. Association between regional ventricular function and myocardial fibrosis in hypertrophic cardiomyopathy assessed by speckle tracking echocardiography and delayed hyperenhancement magnetic resonance imaging. J Am Soc Echocardiogr 2008; 21: 1299-305
  5. Ho JE, Liu C, Lyass A, Courchesne P, Pencina MJ, Vasan RS, et al. Galectin-3, a marker of cardiac fibrosis, predicts incident heart failure in the community. J Am Coll Cardiol 2012; 60: 1249-56
  6. Madrigal-Matute J, Lindholt JS, Fernandez-Garcia CE, BenitoMartin A, Burillo E, Zalba G, et al. Galectin-3, a biomarker linking oxidative stress and inflammation with the clinical outcomes of patients with atherothrombosis. J Am Heart Assoc 2014; 5: 3
  7. Yılmaz H, Gürel OM, Çelik HT, Bozkurt A, Yıldırım ME, Bilgiç I, et al. Relationship of galectin-3 to left ventricular geometry and hypertrophy in chronic hemodialysis patients. Herz 2015; 40: 702-8
  8. Ho JE, Yin X, Levy D, Vasan RS, Magnani JW, Ellinor PT, et al. Galectin 3 and incident atrial fibrillation in the community. Am Heart J 2014; 167: 729-34
  9. Elliott PM, Anastasakis A, Borger MA, Borggrefe M, Cecchi F, Charron P, et al. 2014 ESC Guidelines on diagnosis and management of hypertrophic cardiomyopathy: The Task Force for the Diagnosis and Management of Hypertrophic Cardiomyopathy of the European Society of Cardiology. Eur Heart J 2014; 35: 2733-79
  10. Lang RM, Bierig M, Devereux RB, Flachskampf FA, Foster E, Pellikka PA, et al. American Society of Echocardiography's Nomenclature and Standards Committee; Task Force on Chamber Quantification; American College of Cardiology Echocardiography Committee; American Heart Association; European Association of Echocardiography, Europe